协与医院临床试验报告.pdfVIP

BT½ ÿNK•ˆNý~Š“ f N^ • 11 ..kMING UNION .Uã ..DICAL (1) T^vQv[ƒQ…RlÌu¾uÅY‚u2N¢0^“k#~üT_•{I; (2) N%‘Í€• 0 €¾RŸ€ý_^8€; (3) O•u(•œ\›} l»u—€ ; (4) N%‘Í_Ã0 €º 0 •u¾`£€; (5) N€ýkc^8•Û˜ß€ ; (6) g*[Œb •³˜ß‹°_Ub‹°_Uv„•³˜ßeå‹°N{T|Ö\?uÅ•³˜ßSŸ R € ; (7) g*cqgxzv‰•lB˜ßu( ƒÊ|‰TŒ‘Ñs‰Qp€0 2. xzve¹hH `£€[Œb wå`ÅTaTcqg`R+TŒOS‘ÍcepS9‘Mv„e¹lÕRbƒÊ|‰~Ä 0 ‘Ñs‰Qp~Ä TŒ[ùqg~Ä0N ~ÄW(xzvRM•ÛˆL 1 k!–ÆOS|Ö\?uÅvøQswå‹Æ[£eYTŒ|Ö\?uÅY‚OU™n˜ßv„ eY€² ÿ ^v~ÙkÏOM`£€SÑe|Ö\?uÅ„%Q{wå‹ÆbKQŒTŒ•³˜ß‹°_Uˆhÿ W(xzvg•ôN~ÄWG ‹°_U•³˜ßeå‹° ÿ kÏTh‹°_UNY) ( QvN-N Y)N:Thg+) ÿƒÊ|‰~Ä‘ÇSÖfn•|Ö\?uÅ•³˜ß + ƒÊ|‰15 QK/ Y) 0 ‘Ñs‰Qp~Ä‘ÇSÖfn•|Ö\?uÅ•³˜ß + ‘Ñs‰Qp120 QK/ Y)0[ùqg~ÄSU~¯‘Ç SÖfn•|Ö\?uÅ•³˜ß{Iv„^r˜„e¹lÕ ÿ RR+‰Â[ßWú~¿g0 4 ThTŒ8 TheöN~Ä`£€zz•y ˆ@|Ö0 •œ\›} bµb—cep (HOMA-IR) 0|Ö S ˆ@~¢†Ëv}0 ˆ@•0•ll(‘vTŒ€Œ‰•^r{Ich v„SØS 0kÏThxzvNºTX•ÛˆLu5‹Ý–•‹¿ 1 k!ÿvøQs•î˜˜SïSÊeö_—R0lŸ•TŒ‰ãQ³0‹å xzv]ñˆ«N-VýS;[fyÑ[f–b S N¬SOTŒS;–bOtYÔTXOTa^vbyQÆ0 xzvO•u(v„ƒÊ|‰ ( Vilof @ NanoCPF ) TŒ‘Ñs‰Qpu1N0[•^s[‰šØyÑ[žNg–PQlSø uN§cÐO›0cncÐO›e¹N§TÁ•De™fy:ÿ Vilof @ NanoCPF f/Nåkm2ƒÊ[¦(h90N:SŸe™ÿ ‘Çu(píl4cÐSÖ]å‚z ÿ ^v~Ï•Ç~³nä•œRy»~¯ S b€g/~¯ritR~§Ry»ƒ·_—v„~³|sƒÊ|‰ W‹gœ€Z|Öÿgœ€Z|ÖT+‘Ï86% ÿQvN-v„ON€Zgœ|Ö ( DP 2-9 ) 0N-”þƒÊ|‰ ( DP 10-23 ) TŒY€Zgœ|Ö( DP lè 23 ) T+‘ÏRR+N: 55-70% 0 10-15% TŒ10-15% ÿQvOYT˜ych{ TSku•è 2009 ^te°•Dn•˜ßTÁQlTJ: 3. ‰Â[ßch 3.1 ˆ@m²chmK[š : b@gS×hÀ€zz•y 8h NåN ÿ SÖRM•Â—Y•ˆ@ÿ ‘Çu(Qh•êR¨u SNê (Olympus AU5400 ÿeåg, ) hÀmKˆ@n`;€ÆVú‘‡(TC) 0N‚*ul¹ (TG) 0šØ[Æ^¦•†Ë v}€ÆVú‘‡(HDL- C) 0ON[Æ^¦•†Ëv}€ÆVú‘‡ (LDL- C) 0zz•yˆ@|Ö (FBG) ;|ÖSˆ@~¢†Ëv} (HbA1c) mK[š‘Çu(šØS‹m²vø‚rŒ1lÕÿ zz•yˆ@•œ\›} (In